Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

2025 Issues

Q&A column

August 2025
Q. We manage multispecialty laboratories in multiple hospital locations. Most of the laboratories function on the traditional model of compartmentalized specialty-based testing units that offer routine and specialized services with their own dedicated space, equipment, and personnel. There is a future plan to establish an offsite centralized referral lab, but to improve operational efficiency and cost savings sooner, management is considering consolidating testing services at each location. What factors should be considered while planning the consolidation, keeping in mind the plan to establish a centralized reference lab? Should the testing services that will eventually be performed in the reference lab be excluded from the current consolidation plan? And how should we manage operations during the transition phase, i.e. once consolidation is completed but prior to the reference lab implementation? Read answer.

Q. We have been discussing supervisory review of test results that are manually entered into our laboratory information system (i.e. a test result not sent via interface from an analyzer or autoverified). Examples are a urine hCG performed on a kit cassette or a manual differential performed on a CBC, entered directly into the LIS by the performing technologist. Do manual test results require supervisory review, or is it only higher-complexity tests (like the differential) performed by a medical laboratory technologist that require such review? If review is required, who can review and what is the recommended time frame? Read answer.

External controls critical to crucial assays

August 2025—CAP TODAY publisher Bob McGonnagle spoke on May 14 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Meghan Starolis, MS, PhD, HCLD(ABB), senior science director for infectious diseases at Quest Diagnostics, Chantilly, Va.

Jessica VanAllen
Dr. Van Allen
Dr. Starolis
Dr. Starolis

Read the article:

Bob McGonnagle: Jessica Van Allen, I’d like to talk about some of the hot topics in molecular infectious disease testing, and you mentioned in our discussions offline that viral load testing for transplant viruses is becoming ever more important in the field. Can you make a few remarks about that?

Jessica Van Allen, PhD (Zepto­Metrix): There’s testing that is done using laboratory-developed tests and testing performed using FDA-cleared assays. Those are the two big buckets of testing in the labs of our customers. Meghan and I attended a conference recently at which a couple of the speakers talked about viral load testing for common transplant viruses—EBV, CMV, VZV, some adenoviruses. We’ve been playing in that field for a long time in terms of molecular controls for viruses, so they’re products we’ve had on the shelf. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by ZeptoMetrix.

Put It on the Board

August 2025—In a position statement released in July, the CAP urged policymakers to consider scientific and logistical evidence and to protect the integrity and safety of the national blood supply. The statement was issued in response to legislation proposed in several states that would require blood product labeling based on donor vaccination status or mandate hospitals and blood collectors to honor requests for directed and autologous donations. Misinformation surrounding COVID-19 and mRNA vaccines has led to a growing number of patient requests for blood transfusions exclusively from unvaccinated donors.

Familiar but newer: ICI-associated colitis

July 2025—For all the words that have been devoted to the topic of how to meditate, the path to enlightenment can be disarmingly simple: start by noticing. Likewise, there is a fairly simple set of instructions for untangling one of the vexing problems associated with immune checkpoint inhibitors. Though the drugs can create impressive antitumor response, they can also lead to immune-related adverse events (known as irAEs), including colitis and gastritis, which manifest as histologic changes that can be seen in both the upper and lower gastrointestinal tract. Left unaddressed, severe reactions can disrupt treatment. It’s complicated. And it’s not. The first step, says Raul S. Gonzalez, MD, professor of pathology and laboratory medicine and director of the gastrointestinal pathology service, Emory University School of Medicine, is cultivating a certain mindfulness. “We need to have knowledge that checkpoint inhibitors can cause immune-related adverse events such as gastritis and colitis, to be aware that these things happen,” says Dr. Gonzalez.

Too few phlebotomists—is Aletta the answer?

July 2025—It was one of those infamous winter days in Chicago. The phlebotomy staff were calling off work, and Gregory S. Retzinger, MD, PhD, had reached his breaking point. Phlebotomists tend to be in short supply, and Northwestern Memorial Hospital, where Dr. Retzinger is medical director of pathology clinical services, is no exception.

How high school students are learning about labs

July 2025—Two years into its program to introduce high school students to laboratory careers, Mayo Clinic in Rochester, Minn., is seeing the hoped-for interest and demand. Discover Mayo Clinic Lab Explorers Program is the name, and the program is open to students in grades nine through 12. “Over the last two years, we’ve had roughly 100 students participate, and both times we opened registration it was full within three to five days,” says Liana Michelfelder, talent solutions specialist with the Mayo Clinic human resources workforce development team. In the program’s second year, which took place this year in April, she says, there was a 60-student waiting list. “So we are seeing strong results so far,” Michelfelder says.

Pathology student interest groups—what makes them work

July 2025—Seventy-eight percent of those responding to a survey said their institutions have a pathology student interest group, and they said the most effective ways to engage and retain students are hosting regular events; providing mentorship, leadership, and shadowing opportunities; and offering participation incentives. Using social media and online platforms was reported to be less effective. “A surprise in the findings was the student respondents’ desire to have more faculty engagement. So while students may want to start an interest group and are engaged, they have a hard time getting these off the ground if they don’t have faculty support,” says coauthor Kalisha Hill, MD, MBA. “We’re finding that when the faculty are engaged with these student interest groups, they are much more successful.”

Shorts on Standards: ISO/TS 23824 can help take anatomic pathology quality to another level

July 2025—The International Organization for Standardization (ISO) published a new technical specification, ISO/TS 23824 (Medical Laboratories—Guidance on Application of ISO 15189 in Anatomic Pathology), on the application of ISO 15189 to anatomic pathology. Although structured around the clauses of ISO 15189, the document offers useful guidance, ideas, and concepts applicable to any AP laboratory, including every AP laboratory in the United States that has to comply with CLIA ’88 or CAP Laboratory Accreditation Program requirements.